NVAX Share Price

Open 0.97 Change Price %
High 1.01 1 Day 0.01 1.01
Low 0.97 1 Week -0.03 -2.91
Close 1.00 1 Month -0.48 -32.43
Volume 2716760 1 Year -6.02 -85.75
52 Week High 8.49
52 Week Low 0.73
NVAX Important Levels
Resistance 2 1.04
Resistance 1 1.02
Pivot 0.99
Support 1 0.98
Support 2 0.96
NASDAQ USA Most Active Stocks
DCTH 0.15 -11.76%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
QQQ 141.23 -0.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
FALC 0.25 38.89%
VRTA 4.50 38.46%
ESMC 0.13 30.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
STXS 0.68 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Novavax, Inc. (NASDAQ: NVAX)

NVAX Technical Analysis 5
As on 18th Aug 2017 NVAX Share Price closed @ 1.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.28 & Strong Sell for SHORT-TERM with Stoploss of 1.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVAX Target for August
1st Target up-side 1.5
2nd Target up-side 1.82
3rd Target up-side 2.14
1st Target down-side 0.58
2nd Target down-side 0.26
3rd Target down-side -0.06
NVAX Other Details
Segment EQ
Market Capital 253984256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novavax.com
NVAX Address
NVAX
20 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240-268-2000
NVAX Latest News
Interactive Technical Analysis Chart Novavax, Inc. ( NVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novavax, Inc.
NVAX Business Profile
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.